Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of PEAK Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed ALO-IIT-012(PEAK study), without major protocol deviations.~* Male, or female, 19 years to 75 years.~* Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study~* Subjects completed PEAK can be included within 30 days after End Of the Study~* Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.~Exclusion Criteria:~* eGFR(Epidermal growth factor receptor) \< 50mL/min~* AST(aspartate aminotransferase)/ALT(alanine aminotransaminase) \>2.5 upper limit of normal~* Pregnant or lactating women~* Subject who the investigator deems inappropriate to participate in this study~* Patients with a history of bladder cancer or patients with active bladder cancer~* Patients with uninvestigated macroscopic hematuria~* Patients with cardiac failure or a history of cardiac failure (New York Heart Association \[NYHA\] Stages 3 to 4)~* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- alogliptin+pioglitazone (Type: EXPERIMENTAL): A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
- alogliptin (Type: ACTIVE_COMPARATOR): A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
- pioglitazone (Type: ACTIVE_COMPARATOR): A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation

Based on this trial design, predict the completion outcome and termination type (if applicable).